DE10144903A1 - Vermehrung von Viren in Zellkultur - Google Patents

Vermehrung von Viren in Zellkultur

Info

Publication number
DE10144903A1
DE10144903A1 DE10144903A DE10144903A DE10144903A1 DE 10144903 A1 DE10144903 A1 DE 10144903A1 DE 10144903 A DE10144903 A DE 10144903A DE 10144903 A DE10144903 A DE 10144903A DE 10144903 A1 DE10144903 A1 DE 10144903A1
Authority
DE
Germany
Prior art keywords
virus
cells
medium
viruses
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10144903A
Other languages
German (de)
English (en)
Inventor
Jens-Peter Gregersen
Juergen Vorlop
Christian Frech
Holger Luebben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Chiron Behring GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Behring GmbH and Co KG filed Critical Chiron Behring GmbH and Co KG
Priority to DE10144903A priority Critical patent/DE10144903A1/de
Priority to CA002456561A priority patent/CA2456561A1/en
Priority to AU2002338666A priority patent/AU2002338666B2/en
Priority to BR0212469-6A priority patent/BR0212469A/pt
Priority to HK04104986.4A priority patent/HK1062029B/xx
Priority to ES02777068T priority patent/ES2345606T3/es
Priority to NZ532203A priority patent/NZ532203A/en
Priority to AT02777068T priority patent/ATE466932T1/de
Priority to EP02777068A priority patent/EP1427817B1/de
Priority to DK02777068.4T priority patent/DK1427817T3/da
Priority to US10/487,709 priority patent/US20050118698A1/en
Priority to JP2003527090A priority patent/JP2005502357A/ja
Priority to PCT/EP2002/010207 priority patent/WO2003023025A1/de
Priority to SI200230909T priority patent/SI1427817T1/sl
Priority to PT02777068T priority patent/PT1427817E/pt
Priority to DE50214416T priority patent/DE50214416D1/de
Priority to KR1020047003711A priority patent/KR100968141B1/ko
Publication of DE10144903A1 publication Critical patent/DE10144903A1/de
Priority to JP2010145663A priority patent/JP2010246559A/ja
Priority to CY20101100718T priority patent/CY1110716T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE10144903A 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur Ceased DE10144903A1 (de)

Priority Applications (19)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
DK02777068.4T DK1427817T3 (da) 2001-09-12 2002-09-11 Formering af vira i cellekultur
US10/487,709 US20050118698A1 (en) 2001-09-12 2002-09-11 Multiplication of viruses in a cell culture
BR0212469-6A BR0212469A (pt) 2001-09-12 2002-09-11 Método para multiplicação de vìrus em cultura de célula
HK04104986.4A HK1062029B (en) 2001-09-12 2002-09-11 Multiplication of viruses in a cell culture
ES02777068T ES2345606T3 (es) 2001-09-12 2002-09-11 Multiplicacion de virus en un cultivo celular.
NZ532203A NZ532203A (en) 2001-09-12 2002-09-11 Cell culture system in which cell growth and virus multiplication occur concurrently
AT02777068T ATE466932T1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur
EP02777068A EP1427817B1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur
CA002456561A CA2456561A1 (en) 2001-09-12 2002-09-11 Multiplication of viruses in a cell culture
AU2002338666A AU2002338666B2 (en) 2001-09-12 2002-09-11 Multiplication of viruses in a cell culture
JP2003527090A JP2005502357A (ja) 2001-09-12 2002-09-11 細胞培養物中のウイルス増殖
PCT/EP2002/010207 WO2003023025A1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur
SI200230909T SI1427817T1 (sl) 2001-09-12 2002-09-11 Razmnoževanje virusov in celičnih kultur
PT02777068T PT1427817E (pt) 2001-09-12 2002-09-11 Multiplicação de vírus numa cultura celular
DE50214416T DE50214416D1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur
KR1020047003711A KR100968141B1 (ko) 2001-09-12 2002-09-11 세포 배양물에서 바이러스의 증식 방법
JP2010145663A JP2010246559A (ja) 2001-09-12 2010-06-25 細胞培養物中のウイルス増殖
CY20101100718T CY1110716T1 (el) 2001-09-12 2010-07-30 Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur

Publications (1)

Publication Number Publication Date
DE10144903A1 true DE10144903A1 (de) 2003-03-27

Family

ID=7698761

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10144903A Ceased DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
DE50214416T Expired - Lifetime DE50214416D1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50214416T Expired - Lifetime DE50214416D1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur

Country Status (16)

Country Link
US (1) US20050118698A1 (https=)
EP (1) EP1427817B1 (https=)
JP (2) JP2005502357A (https=)
KR (1) KR100968141B1 (https=)
AT (1) ATE466932T1 (https=)
AU (1) AU2002338666B2 (https=)
BR (1) BR0212469A (https=)
CA (1) CA2456561A1 (https=)
CY (1) CY1110716T1 (https=)
DE (2) DE10144903A1 (https=)
DK (1) DK1427817T3 (https=)
ES (1) ES2345606T3 (https=)
NZ (1) NZ532203A (https=)
PT (1) PT1427817E (https=)
SI (1) SI1427817T1 (https=)
WO (1) WO2003023025A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537760A (ja) * 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (en) * 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2615167A1 (en) 2006-09-15 2013-07-17 MedImmune, LLC Method for eliminating DNA contaminants from viral preparations
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
EP2344634A4 (en) 2008-09-24 2012-08-29 Medimmune Llc METHODS OF CELL CULTURE, AND PROPAGATION AND PURIFICATION OF VIRUSES
CA2741961A1 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
CA2778332A1 (en) * 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
SG192821A1 (en) * 2011-02-17 2013-09-30 Boehringer Ingelheim Vetmed Commercial scale process for production of prrsv
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2822585B1 (en) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Improved vaccination against influenza
WO2014031480A1 (en) * 2012-08-24 2014-02-27 Xcellerex, Inc. Virus purification and formulation process
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
KR102790570B1 (ko) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
CN108239619A (zh) * 2016-12-23 2018-07-03 甘肃健顺生物科技有限公司 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术
CN108570444A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 St细胞驯化悬浮方法和二阶病毒生产工艺
CN108570445A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Pk15细胞驯化悬浮方法和二阶病毒生产工艺
CN108570454A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Mdbk驯化悬浮方法和二阶病毒生产工艺
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037000A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990072201A (ko) * 1996-10-18 1999-09-27 무타이 마사히꼬 로타바이러스 항원, 로타바이러스 감염증에 대한백신 및 진단제와 항원 제조방법
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
KR100797547B1 (ko) * 2000-03-03 2008-01-24 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037000A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses

Also Published As

Publication number Publication date
HK1062029A1 (zh) 2004-10-15
SI1427817T1 (sl) 2010-08-31
DK1427817T3 (da) 2010-08-23
CY1110716T1 (el) 2015-06-10
ES2345606T3 (es) 2010-09-28
BR0212469A (pt) 2004-08-24
ATE466932T1 (de) 2010-05-15
PT1427817E (pt) 2010-08-10
US20050118698A1 (en) 2005-06-02
AU2002338666B2 (en) 2008-11-20
JP2005502357A (ja) 2005-01-27
KR100968141B1 (ko) 2010-07-06
CA2456561A1 (en) 2003-03-20
EP1427817B1 (de) 2010-05-05
WO2003023025A1 (de) 2003-03-20
DE50214416D1 (de) 2010-06-17
KR20050027164A (ko) 2005-03-17
NZ532203A (en) 2005-04-29
EP1427817A1 (de) 2004-06-16
JP2010246559A (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
DE10144906B4 (de) Verfahren zur großtechnischen Herstellung von Impfstoffen
EP1427817B1 (de) Vermehrung von viren in zellkultur
DE19612966B4 (de) MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE69732407T3 (de) Verfahren für die Replikation von Influenza in Zellkultur und die bei diesem Verfahren hergestellten Influenza-Viren
DE4407489A1 (de) Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
DE69923470T2 (de) Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion
CH504532A (de) Verfahren zur Züchtung pathogener Viren, Zellstamm zur Ausführung des Verfahrens und Anwendung des Verfahrens
EP0019218B1 (de) Influenzavirus-Vaccine, Verfahren zu ihrer Herstellung und Verfahren zur Vermehrung von Influenzaviren
DE2463143C2 (de) Polyvalente Rindervirus-Lebendimpfstoffe
EP2606128B1 (de) Permanente humane amniozyten zellinie zur herstellung von influenzaviren
DE19655440B4 (de) Verfahren zur Herstellung eines Influenzaimpfstoffs
El-Bagoury et al. Comparative potentiality study of three different vero cell culture systems for production of PPR Vaccine
HK1149046A (en) Method for manufacturing an active component of a medicine or diagnosis agent in mdcj cell suspension culture
DE2553827A1 (de) Wachstumsmedium fuer zellkulturen, verfahren zu seiner herstellung, zellkultivierungsverfahren und virusimpfstoff
HK1062029B (en) Multiplication of viruses in a cell culture

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8125 Change of the main classification

Ipc: A61K 35/76 AFI20051017BHDE

R081 Change of applicant/patentee

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNER: CHIRON BEHRING GMBH & CO., 35039 MARBURG, DE

Effective date: 20110615

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, DE

Free format text: FORMER OWNER: CHIRON BEHRING GMBH & CO., 35039 MARBURG, DE

Effective date: 20110615

R082 Change of representative

Representative=s name: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- , DE

Effective date: 20110615

Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG, DE

Representative=s name: UEXKUELL & STOLBERG, DE

Effective date: 20110615

R082 Change of representative

Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG, DE

Representative=s name: UEXKUELL & STOLBERG, DE

R081 Change of applicant/patentee

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, 35041 MARBURG, DE

Effective date: 20111209

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, DE

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, 35041 MARBURG, DE

Effective date: 20111209

R082 Change of representative

Representative=s name: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- , DE

Effective date: 20111209

Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG, DE

Representative=s name: UEXKUELL & STOLBERG, DE

Effective date: 20111209

R016 Response to examination communication
R081 Change of applicant/patentee

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, 35041 MARBURG, DE

R082 Change of representative

Representative=s name: UEXKUELL & STOLBERG, DE

Representative=s name: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- , DE

R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final